Glial Cell-Mediated Neuroinflammation in Alzheimer's Disease

Int J Mol Sci. 2022 Sep 12;23(18):10572. doi: 10.3390/ijms231810572.

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder; it is the most common cause of dementia and has no treatment. It is characterized by two pathological hallmarks, the extracellular deposits of amyloid beta (Aβ) and the intraneuronal deposits of Neurofibrillary tangles (NFTs). Yet, those two hallmarks do not explain the full pathology seen with AD, suggesting the involvement of other mechanisms. Neuroinflammation could offer another explanation for the progression of the disease. This review provides an overview of recent advances on the role of the immune cells' microglia and astrocytes in neuroinflammation. In AD, microglia and astrocytes become reactive by several mechanisms leading to the release of proinflammatory cytokines that cause further neuronal damage. We then provide updates on neuroinflammation diagnostic markers and investigational therapeutics currently in clinical trials to target neuroinflammation.

Keywords: Alzheimer’s disease; astrocytes; clinical trials; diagnostic markers; microglia; neuroinflammation; therapeutics.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease* / pathology
  • Amyloid beta-Peptides
  • Cytokines
  • Humans
  • Microglia / pathology
  • Neuroglia / pathology
  • Neuroinflammatory Diseases

Substances

  • Amyloid beta-Peptides
  • Cytokines

Grants and funding

This research received no external funding.